



BUILDING ONTO THE CLINICAL EXPERIENCE OF TRASTUZUMAB WITH PFIZER

For early or metastatic HER2+ breast cancer patients, there is an additional option for trastuzumab treatment¹

In patients with HER2+ metastatic breast cancer and in patients with HER2+ early-stage breast cancer, TRAZIMERA showed efficacy and safety profiles similar to those of the reference product, Herceptin® (trastuzumab)^{2,3}

TRAZIMERA is part of a large oncological biosimilar portfolio from Pfizer^{1,4-8}

TRAZIMERA has the potential to create savings and efficiencies for the healthcare system⁹

Summary of Product Characteristics available [here](#).

www.pfizer.com

References: 1. TRAZIMERA® Summary of Product Characteristics. 2. Pegram MD, Bondarenko I, Moreira Costa Zorzetto M. PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomized, double-blind study. *Brit J Cancer*. 2019;120(2):172-182. 3. Lammers PE, Dank M, Masetti R, et al. Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. *Br J Cancer*. 2018;119(3):266-273. 4. ZIRABEV® Summary of Product Characteristics. 5. RUXIENCE® Summary of Product Characteristics. 6. NYVEPRIA® Summary of Product Characteristics. 7. NIVESTIM™ Summary of Product Characteristics. 8. RETACRIT™ Summary of Product Characteristics. 9. IQVIA. The impact of biosimilar competition in Europe. https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2021.pdf?_=1640100592119. Updated December 2021. Accessed March 24, 2022.